证券代码：603259 证券简称：药明康德 公告编号：临 2026-001 无锡药明康德新药开发股份有限公司 股东减持股份结果公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 公司董事会及全体董事保证公告内容与相关股东提供的信息一致。 重要内容提示： 股东持股的基本情况 根据无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日披露的《股东减持股份计划公告》（公告编号：临 2025-070），本次 减持计划实施前公司实际控制人控制的股东合计持有公司 A 股股份 543,364,675 股，占公司总股本的 18.211%。该等股份均为公司首次公开发行 A 股股票并上市 前所取得的股份及上市后权益分派资本公积转增股本方式取得的股份，均为无限 售条件流通股。 减持计划的实施结果情况 公司于 2026 年 1 月 5 日收到实际控制人控制的股东发出的《告知函》，截 至 2026 年 1 月 5 日，实际控制人控制的股东通过集中竞价和大宗交易方式累计 减持公司股份 59,675,143 股，占公司总股本的 2%。本次减持计划已实施完毕。 股东名 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 RMB | | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 RMB | | | 1 RMB | | 510,476,909 | 由於無錫藥明康德新藥開發股份有限公司(「本公司」)在中 ...

Core Viewpoint - The company, WuXi AppTec, is experiencing positive market performance, with a recent stock increase of 1.78% and a total market capitalization of 287.87 billion yuan, benefiting from its position as a leading Contract Research Organization (CRO) and the depreciation of the Chinese yuan [1][3]. Group 1: Company Overview - WuXi AppTec is an international leader in providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2]. - The company is a domestic leader in the pharmaceutical outsourcing industry, being one of the earliest to engage in CRO and CMO integrated services, with over 200 authorized and pending patent achievements [2]. - The main business involves the discovery, research, and production of small molecule chemical drugs, offering a full range of services to global pharmaceutical companies [2][7]. Group 2: Financial Performance - For the period ending September 30, 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion yuan, reflecting an 84.84% increase [7]. - The company’s revenue from overseas accounts for 78.67%, benefiting from the depreciation of the yuan [3]. - The revenue composition includes 78.37% from chemical business, 12.93% from testing services, 6.02% from biological services, and 1.90% from other supplementary services [7]. Group 3: Market Activity - The stock has seen a net inflow of 1.84 million yuan from major investors today, with a total net inflow of 2.38 million yuan over the last three days [4][5]. - The average trading cost of the stock is 95.67 yuan, with the current price approaching a resistance level of 96.50 yuan, indicating potential for upward movement if this level is surpassed [6].

两融数据显示，该股最新融资余额为68.12亿元，近5日减少3.88亿元，降幅为5.38%。（数据宝） （原标题：药明康德现19笔大宗交易 合计成交1033.84万股） 药明康德1月5日大宗交易平台共发生19笔成交，合计成交量1033.84万股，成交金额9.29亿元。成交价格 均为89.84元，相对今日收盘价折价5.00%。从参与大宗交易营业部来看，机构专用席位共出现在4笔成 交的买方或卖方营业部中，合计成交金额为6.11亿元，净买入6.11亿元。 进一步统计，近3个月内该股累计发生62笔大宗交易，合计成交金额为26.27亿元。 证券时报•数据宝统计显示，药明康德今日收盘价为94.57元，上涨4.34%，日换手率为2.95%，成交额为 68.80亿元，全天主力资金净流入1.48亿元，近5日该股累计上涨2.86%，近5日资金合计净流出6.27亿 元。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 1月5日药明康德大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当 日 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额 | 格 | 收盘 ...

Core Viewpoint - In 2025, the level of cash dividends from listed companies is expected to rise, transitioning capital returns from an "optional" to a "mandatory" aspect, influenced by strengthened regulatory constraints and a clearer preference for long-term capital [1][3] Group 1: Company Performance and Shareholder Returns - As of December 25, A-share listed companies have distributed over 2.61 trillion yuan in cash dividends this year, marking a historical high [1] - WuXi AppTec, as a leading CXO enterprise, has demonstrated a strong shareholder return strategy through a combination of cash dividends and share buybacks, signaling stable and clear returns to the market [1] - WuXi AppTec has announced a total cash dividend of 4.88 billion yuan for 2024 and 2025, along with two share buybacks totaling 2 billion yuan, enhancing shareholder value by reducing the number of shares outstanding [1][2] Group 2: Financial Stability and Cash Flow - WuXi AppTec's net cash flow from operating activities reached 10.87 billion yuan, reflecting a 35% year-on-year increase, which supports high levels of shareholder returns [2] - The company has maintained a stable cash dividend policy since its IPO in 2018, with a long-term payout ratio around 30%, further reinforcing its commitment to shareholder returns [2] Group 3: Market and Regulatory Context - Regulatory bodies have increasingly enforced cash dividend policies, shifting from "advisory arrangements" to "binding rules," which enhances the importance of capital return methods in valuation structures [3] - Sustainable and predictable dividend arrangements, along with share buyback strategies aligned with stock price cycles, are becoming key indicators of corporate governance quality and capital efficiency [3] - WuXi AppTec's approach to dividends and buybacks is viewed as a long-term commitment to providing tangible and sustainable capital returns, addressing market expectations for certainty and long-term value [3]

Market Overview - The Shanghai Composite Index rose by 0.09% on December 31, with 15 industries experiencing gains, led by defense and military industry at 2.13% and media at 1.54% [1] - The communication and agriculture, forestry, animal husbandry, and fishery sectors saw the largest declines, down 1.35% and 1.10% respectively [1] - The pharmaceutical and biotechnology sector fell by 0.45% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 32.27 billion yuan, with 9 industries seeing net inflows [1] - The defense and military industry had the highest net inflow of 6.06 billion yuan, followed by the media sector with 4.45 billion yuan [1] - A total of 22 industries experienced net capital outflows, with the electronics sector leading at 11.20 billion yuan, followed by the power equipment sector at 7.25 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 3.54 billion yuan, with 178 of the 478 stocks in the sector rising and 276 falling, including one stock hitting the daily limit down [2] - The top three stocks with net inflows in this sector were Meinian Health (84.95 million yuan), Huaren Health (75.69 million yuan), and Xingqi Eye Medicine (64.86 million yuan) [2] - The stocks with the largest net outflows included WuXi AppTec (468.14 million yuan), Mindray Medical (321.35 million yuan), and Hefei China (276.65 million yuan) [3]

Group 1 - The core point of the news is that WuXi AppTec's stock price increased by 1.47% to 93.25 CNY per share, with a total market capitalization of 278.235 billion CNY as of December 31 [1] - WuXi AppTec, established on December 1, 2000, provides a comprehensive platform for the discovery, development, and manufacturing of small molecule chemical drugs, serving global pharmaceutical companies [1] - The company's revenue composition includes 78.37% from chemical business, 12.93% from testing services, 6.02% from biological services, and 1.90% from other supplementary services [1] Group 2 - According to data, a fund under Guorong Fund holds a significant position in WuXi AppTec, with 5,000 shares representing 3.89% of the fund's net value, making it the sixth-largest holding [2] - The Guorong Rongxin Consumer Select Mixed A fund has a total scale of 10.3913 million CNY and has experienced a loss of 0.4% this year, ranking 7867 out of 8085 in its category [2] - The fund has also incurred a loss of 6.75% since its inception on June 19, 2019 [2]

Group 1 - Core viewpoint: WuXi AppTec is a leading integrated CRDMO provider, delivering efficient global services for the pharmaceutical and life sciences industry through continuous internal and external development [2][13] - The company has a highly experienced management team with a global perspective and is implementing an H-share incentive trust plan to attract and motivate key talent [2][13] - The CRDMO integration is expected to see a slight revenue decline in 2024, but the performance in the first half of 2025 is anticipated to be strong [2][13] Group 2 - The CXO industry is experiencing robust growth due to the long development times, high costs, and low success rates of drug development, leading to a trend of specialization in the pharmaceutical R&D service sector [3][14] - The rapid release of demand in China's pharmaceutical market, along with the increasing trend of refined specialization and the promotion of hierarchical diagnosis and treatment, is driving the prosperity of the CRO industry [3][14] - Pharmaceutical companies' demands for cost control and efficiency improvements are pushing CMO companies to upgrade to CDMO enterprises, resulting in steady growth in the global CDMO market, particularly in China [3][14] Group 3 - WuXi Chemistry offers integrated services with strong capital requirements and high customer stickiness, creating high barriers for CRDMO one-stop services [4][15] - The R&D business has a strong research capability, continuously attracting high-quality molecules, with 621 new molecules added to the D&M pipeline from Q1 to Q3 of 2025, including 250 molecules transitioning from R to D [4][15] - The D&M business is steadily growing in areas such as API services, formulation services, analytical services, and global regulatory affairs support, with a total of 3,430 small molecule D&M pipeline projects expected by the end of September 2025 [4][15] Group 4 - WuXi Testing provides testing solutions, although revenue has fluctuated in recent years [5][16] - The WIND platform offers integrated laboratory analysis and testing services, helping clients shorten drug development timelines while continuously enhancing capacity and global business layout [5][16] - The company has divested its clinical CRO and SMO services, focusing on core business areas, which has been impacted by market pricing factors leading to revenue declines in Q1 to Q3 of 2025 [5][16] Group 5 - WuXi Biology offers comprehensive biological services and solutions, covering all stages of drug discovery and major disease areas, while continuously building capabilities related to new molecular types [6][17] - The company is strengthening its capabilities in drug discovery hotspots and proactively expanding overseas business to efficiently drive the CRDMO business model [6][17] Group 6 - Profit forecast: Under a neutral scenario, the company expects net profit attributable to shareholders to be 15.86 billion, 15.22 billion, and 17.63 billion yuan for 2025-2027, with EPS of 5.32, 5.10, and 5.91 yuan per share, respectively [7][18] - The corresponding PE for 2025 is projected to be 17.44 times, with an initial coverage rating of "Accumulate" [7][18]

Group 1 - The core point of the news is that WuXi AppTec conducted a block trade on December 30, with a total of 71,700 shares traded, amounting to 6.5964 million yuan, which represents 0.23% of the total trading volume for that day [1][2] - The transaction price was 92 yuan per share, which is a premium of 0.11% compared to the market closing price of 91.9 yuan [1][2]

Core Viewpoint - WuXi AppTec is positioned as a leading integrated CRDMO provider, delivering efficient services to the global pharmaceutical and life sciences industry through continuous internal and external development [1] Group 1: Company Overview - WuXi AppTec offers integrated, end-to-end new drug research and production services [1] - The management team possesses extensive experience in the pharmaceutical industry and has a global perspective [1] - The company is actively launching H-share incentive trust plans to attract and motivate key talent [1] Group 2: Financial Performance - The integrated CRDMO segment is expected to experience a slight revenue decline in 2024, but the performance in the first half of 2025 is anticipated to be strong [1] - The initial coverage of the company has been rated as "Buy" [1]